Nautilus Biotechnology, Inc. (NAUT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Nautilus Biotechnology (NAUT) Q2 2026: Proteoform R&D Headcount Triples as Broad Scale Timeline Slips
  July 28, 2026
• Nautilus Biotechnology (NAUT) Q1 2026: Operating Expenses Fall 14% as Commercial Launch Readiness Advances
  June 16, 2026
• Nautilus Biotechnology (NAUT) Q2 2025: Operating Expenses Down 18% as Platform Validation Accelerates
  June 16, 2026
• Nautilus (NAUT) Q3 2025: OpEx Down 19% as Platform Readies for Early Access Expansion
  June 16, 2026
• Nautilus Biotechnology (NAUT) Q4 2025: Operating Expenses Down 23% as Platform Nears Commercialization
  June 15, 2026
• Nautilus (NAUT) Q1 2025: Operating Expenses Down 13% as Platform Readiness Accelerates
  July 07, 2025

Browse all companies